TransMedics Group Inc.
Last updated September 27, 2026
Organization details
- Legal name
- TransMedics Group Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TMDX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001756262
Board of directors
-
David Weill · DirectorSince 2023
-
Edward M. Basile · DirectorSince 2023
-
Edwin M. Kania Jr. · DirectorSince 2023
-
James R. Tobin · DirectorSince 2023
-
Merilee Raines · DirectorSince 2023
-
Stephanie Lovell · DirectorSince 2023
-
Thomas James Gunderson · DirectorSince 2023
-
Waleed H. Hassanein · Director · President & CEOSince 2023
Chief executives
Waleed H. Hassanein
· President & CEO
Dates unknown
Board connections
3 of this board's directors also sit on 4 other boards.
- via James R. Tobin
- via Thomas James Gunderson
- via Merilee Raines
- via Merilee Raines
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 9, 2024 | Hernandez Gerardo Officer (Chief Financial Officer) | Grant or award | +12,463 | — | — |
| Dec 2, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Option exercise | +1,084 | $13.28 | $14,396 |
| Dec 2, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Open-market sale | −1,084 | $86.40 | $93,658 |
| Nov 11, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Option exercise | +1,458 | $38.46 | $56,075 |
| Nov 11, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Open-market sale | −1,458 | $90.04 | $131,278 |
| Nov 5, 2024 | Edward M. Basile Director | Option exercise | +6,750 | $28.12 | $189,810 |
| Nov 5, 2024 | Edward M. Basile Director | Open-market sale | −5,296 | $83.35 | $441,422 |
| Nov 5, 2024 | Edward M. Basile Director | Open-market sale | −1,454 | $84.30 | $122,572 |
| Nov 1, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Option exercise | +1,083 | $13.28 | $14,382 |
| Nov 1, 2024 | Khayal Tamer I Officer (Chief Commercial Officer) | Open-market sale | −1,083 | $82.64 | $89,499 |
| Oct 15, 2024 | Waleed H. Hassanein Director, Officer (President & CEO) | Option exercise | +8,625 | $13.28 | $114,540 |
| Oct 15, 2024 | Waleed H. Hassanein Director, Officer (President & CEO) | Open-market sale | −3,607 | $131.91 | $475,799 |
| Oct 15, 2024 | Waleed H. Hassanein Director, Officer (President & CEO) | Open-market sale | −3,518 | $132.82 | $467,261 |
| Oct 15, 2024 | Waleed H. Hassanein Director, Officer (President & CEO) | Open-market sale | −1,200 | $134.23 | $161,076 |
| Oct 15, 2024 | Waleed H. Hassanein Director, Officer (President & CEO) | Open-market sale | −300 | $135.04 | $40,512 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.